Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2024-02-08

EMA Authorised: Ambirix (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

Ambirix has been authorised for immunization against hepatitis A and hepatitis B infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambirix

Snippet

Status: Authorised. Therapeutic area: Hepatitis B;Hepatitis A;Immunization. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 01/02/2024